Abstract
Objective
To observe the efficacy and safety of Guihuang Formula (GHF) in treating patients with type III prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis.
Methods
Sixty-six patients diagnosed with type III prostatitis with dampness-heat and blood stasis syndrome were randomly divided into the treatment group (GHF) and the control group (tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs).
Results
After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups (P<0.05). The CMSS score decreased in both groups (P<0.05). The WBC count decreased and lecithin body count increased in both groups (P<0.05). GHF showed a more obvious advantage in reducing the pain discomfort and quality of life domain scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of the WBC and lecithin body counts, compared with the control group (P<0.05). There were no significant differences in decreasing urination domain score of NIH-CPSI between two groups (P>0.05). In addition, no serious AEs were observed.
Conclusion
GHF is effective in treating type III prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs. (Registration No. ChiCTR1900026966)
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Polackwich AS, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer P D 2016;19:132–138.
Liu SJ, Gao QH, Deng YJ, Zen Y, Zhao M, Guo J. Knowledge domain and emerging trends in chronic prostatitis/chronic pelvic pain syndrome from 1970 to 2020: a scientometric analysis based on VOSviewer and CiteSpace. Ann Palliat Med 2022 [Epub ahead of print].
Rees J, Abrahams M, Doble A, Cooper A; Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int 2015;116:509–525.
Liu SJ, Gao QH, Deng YJ, Du GC, Guo J, Zhao F, et al. Analysis of current research status of diagnosis and treatment of chronic prostatitis by Chinese medicine based on knowledge mapping. Chin J Integr Tradit West Med (Chin) 2021;41:817–822.
Clemens JQ, Mullins C, Ackerman AL, Bavendam T, van Bokhoven A, Ellingson BM, et al. Urologic chronic pelvic pain syndrome: insights from the MAPP research network. Nat Rev Urol 2019;16:187–200.
Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-Blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2012;110:1014–1022.
Jun G. Thinking on integrated Chinese and Western medicine in chronic prostatitis based on UPOINT. Chin J Integr Tradit West Med 2018;38:517–519.
Zhang MJ, Bin B, Shang XJ, Deng SM, Wang WC, Zhou SH, et al. Expert consensus on the diagnosis and treatment of chronic prostatitis in the integrative medicine. Chin J Integr Tradit West Med (Chin) 2015;35:933–941.
Huang J, ed. 2019 Guidelines for the diagnosis and treatment of urological and andrological diseases in China. Beijing: people’s Medical Publishing House; 2019:441–442.
Litwin MS, McNaughton-Collins M, Fowler FJ, Jr. Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369–375.
Liu SJ, Wang F, Zhang JW, Yan B, Liu Y, Gao QH. GUO Jun’s experience in treating chronic prostatitis based on sore-ulcer-resolving therapy. World J Integr Tradit West Med (Chin) 2020;15:263–265, 269.
Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, Nickel JC. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2016;69:286–297.
Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W, et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2013;63:953–959.
Jin BF, Yang WT, Sun DL, Li HJ. Current situation and reconsideration on the study of integrated Chinese and Western medicine andrology. Chin J Integr Med 2020;26:388–392.
Ying J, Zhou MJ, Chen HY, Chen L, Zhang W, Ji J, et al. Effect of essential oil on patients with chronic prostatitis/chronic pelvic pain syndrome: a pilot randomized controlled trial. Chin J Integr Med 2019;25:91–95.
Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, et al. Comprehensive overview of prostatitis. Biomed Pharmacother 2017;94:1064–1076.
Franco JVA, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int 2020;125:490–496.
Li J, Wei Y, Li X, Zhu D, Nie B, Zhou J, et al. Herbal formula Xian-Fang-Huo-Ming-Yin regulates differentiation of lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis mice. BMC Complement Altern Med 2017;17:12.
Pan PK. Clinical observation of the treatment of chronic prostatitis of blood stasis with modified Xian Fang Huo Ming Yin [Dissertation]. Heilongjiang: Heilongjiang University of Chinese Medicine; 2011.
Liu SJ. Clinical observation of Guihuang Formula in treating patients with type M prostatitis of damp heat and blood stasis syndrome and experimental study on regulatory PI3K/Akt/NF-κ B pathway [Dissertation]. Beijing: Beijing University of Traditional Chinese Medicine; 2021.
Author information
Authors and Affiliations
Contributions
Gao QH and Guo J contributed to research implementation, experiment supervision, and fund managers. Liu SJ contributed to the writing of the paper and experimental design. Zeng Y and Zhao M contributed to the data analysis. Liu SJ, Deng YJ, ZY, Guo J, and Gao QH participated in the experiments.
Corresponding author
Additional information
Conflict of Interest
There is no conflict of interest.
Supported by the National Natural Science Foundation of China (No. 82104880), Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (No. CI2021A02208) and the Nursery Project of Xiyuan Hospital of China Academy of Chinese Medical Sciences (No. 2019XYMP-23)
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Liu, Sj., Deng, Yj., Zeng, Y. et al. Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial. Chin. J. Integr. Med. 28, 879–884 (2022). https://doi.org/10.1007/s11655-022-3467-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-022-3467-1